The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions - PubMed (original) (raw)
Affiliations
- PMID: 19414323
Free article
Case Reports
The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions
Junji Wada et al. Anticancer Res. 2009 Mar.
Free article
Abstract
It has been suggested that immunosuppressive cytokines such as transforming growth factor beta (TGF-beta) and interleukin 10 play an important role in the induction and/or maintenance of regulatory T-cells (Tregs) in patients with cancer. In the present study, whether or not vascular endothelial growth factor (VEGF) contributes to the induction and/or maintenance of Tregs was examined, because of experience with a patient in whom a positive correlation between VEGF concentration and the percentage of Tregs (% Tregs) among the total CD4(+) T-cells in the pleural effusion was found during dendritic cell activated lymphocyte therapy. CD4(+)CD25(high) T-cells were estimated as Tregs in the present study. In an in vitro experimental system, VEGF-containing malignant effusions increased the % Tregs in autologous peripheral blood mononuclear cells (PBMCs), which could be suppressed by the addition of a humanized monoclonal anti-VEGF antibody (bevacizumab [Avastin]). When VEGF-producing hepatic carcinoma cells were mix-cultured with PBMCs, the % Tregs increased and this increase was also suppressed by the addition of bevacizumab. Whether or not bevacizumab can affect the % Tregs of PBMCs in patients with colon cancer was also examined. Three out of four patients showed a significant decrease of the % Tregs after intravenous injection of bevacizumab. Interestingly, the expression of VEGF receptor-2 (VEGFR-2) was higher in Tregs than in other CD4(+) T-cells. Taken together, the data presented here indicate a contribution of VEGF to induction and/or maintenance of Tregs in patients with cancer.
Similar articles
- CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion.
Chen YQ, Shi HZ, Qin XJ, Mo WN, Liang XD, Huang ZX, Yang HB, Wu C. Chen YQ, et al. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1434-9. doi: 10.1164/rccm.200504-588OC. Epub 2005 Sep 8. Am J Respir Crit Care Med. 2005. PMID: 16151041 - Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients.
Wada J, Yamasaki A, Nagai S, Yanai K, Fuchino K, Kameda C, Tanaka H, Koga K, Nakashima H, Nakamura M, Tanaka M, Katano M, Morisaki T. Wada J, et al. Anticancer Res. 2008 Jul-Aug;28(4C):2401-8. Anticancer Res. 2008. PMID: 18751426 - Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells.
Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G. Calvani M, et al. Cancer Res. 2008 Jan 1;68(1):285-91. doi: 10.1158/0008-5472.CAN-07-5564. Cancer Res. 2008. PMID: 18172321 - Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N, Hillan KJ, Novotny W. Ferrara N, et al. Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35. doi: 10.1016/j.bbrc.2005.05.132. Biochem Biophys Res Commun. 2005. PMID: 15961063 Review. - The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.
Bradshaw M, Mansfield A, Peikert T. Bradshaw M, et al. Curr Oncol Rep. 2013 Jun;15(3):207-16. doi: 10.1007/s11912-013-0315-7. Curr Oncol Rep. 2013. PMID: 23568600 Free PMC article. Review.
Cited by
- The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer.
Sun X, Zhang Z, Wang Z, Xie R, Yi C, Liu H, Chi X, Li T, Liu H, Han Y, Pang X, Cui Y, Liu Z. Sun X, et al. Front Immunol. 2022 Nov 21;13:1033967. doi: 10.3389/fimmu.2022.1033967. eCollection 2022. Front Immunol. 2022. PMID: 36479101 Free PMC article. - Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.
Mirando AC, Patil A, Rafie CI, Christmas BJ, Pandey NB, Stearns V, Jaffee EM, Roussos Torres ET, Popel AS. Mirando AC, et al. Oncoimmunology. 2020 May 14;9(1):1760685. doi: 10.1080/2162402X.2020.1760685. Oncoimmunology. 2020. PMID: 32923118 Free PMC article. - Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis.
Tabana Y, Okoye IS, Siraki A, Elahi S, Barakat KH. Tabana Y, et al. Front Oncol. 2021 Mar 5;11:628138. doi: 10.3389/fonc.2021.628138. eCollection 2021. Front Oncol. 2021. PMID: 33747948 Free PMC article. Review. - Immunosuppressive effects of vascular endothelial growth factor.
Ribatti D. Ribatti D. Oncol Lett. 2022 Sep 1;24(4):369. doi: 10.3892/ol.2022.13489. eCollection 2022 Oct. Oncol Lett. 2022. PMID: 36238855 Free PMC article. Review. - Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy?
Szala S, Mitrus I, Sochanik A. Szala S, et al. Cancer Immunol Immunother. 2010 Oct;59(10):1449-55. doi: 10.1007/s00262-010-0873-6. Epub 2010 Jun 16. Cancer Immunol Immunother. 2010. PMID: 20552191 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials